373 related articles for article (PubMed ID: 30447328)
21. GABA function in mood disorders: an update and critical review.
Shiah IS; Yatham LN
Life Sci; 1998; 63(15):1289-303. PubMed ID: 9768867
[TBL] [Abstract][Full Text] [Related]
22. Glutamate and GABA contributions to medial prefrontal cortical activity to emotion: implications for mood disorders.
Stan AD; Schirda CV; Bertocci MA; Bebko GM; Kronhaus DM; Aslam HA; LaBarbara EJ; Tanase C; Lockovich JC; Pollock MH; Stiffler RS; Phillips ML
Psychiatry Res; 2014 Sep; 223(3):253-60. PubMed ID: 24973815
[TBL] [Abstract][Full Text] [Related]
23. Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine.
Lener MS; Niciu MJ; Ballard ED; Park M; Park LT; Nugent AC; Zarate CA
Biol Psychiatry; 2017 May; 81(10):886-897. PubMed ID: 27449797
[TBL] [Abstract][Full Text] [Related]
24. Keeping up with the clinical advances: depression.
Ragguett RM; Tamura JK; McIntyre RS
CNS Spectr; 2019 Aug; 24(S1):25-37. PubMed ID: 31248466
[TBL] [Abstract][Full Text] [Related]
25. Glutamatergic dysregulation in mood disorders: opportunities for the discovery of novel drug targets.
Małgorzata P; Paweł K; Iwona ML; Brzostek T; Andrzej P
Expert Opin Ther Targets; 2020 Dec; 24(12):1187-1209. PubMed ID: 33138678
[TBL] [Abstract][Full Text] [Related]
26. Metabotropic glutamate receptors in the control of mood disorders.
Witkin JM; Marek GJ; Johnson BG; Schoepp DD
CNS Neurol Disord Drug Targets; 2007 Apr; 6(2):87-100. PubMed ID: 17430147
[TBL] [Abstract][Full Text] [Related]
27. Astroglial Connexin43 as a Potential Target for a Mood Stabiliser.
Okada M; Oka T; Nakamoto M; Fukuyama K; Shiroyama T
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396966
[TBL] [Abstract][Full Text] [Related]
28. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.
Niciu MJ; Ionescu DF; Richards EM; Zarate CA
J Neural Transm (Vienna); 2014 Aug; 121(8):907-24. PubMed ID: 24318540
[TBL] [Abstract][Full Text] [Related]
29. [Rapid-acting antidepressants-neurobiological mechanisms of action].
Gass P; Vasilescu AN; Inta D
Nervenarzt; 2022 Mar; 93(3):223-233. PubMed ID: 34766186
[TBL] [Abstract][Full Text] [Related]
30. GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action.
Sanacora G; Saricicek A
CNS Neurol Disord Drug Targets; 2007 Apr; 6(2):127-40. PubMed ID: 17430150
[TBL] [Abstract][Full Text] [Related]
31. Update on antidepressants.
O'Shanick GJ
J Head Trauma Rehabil; 2006; 21(3):282-4. PubMed ID: 16717506
[No Abstract] [Full Text] [Related]
32. Antidepressant drugs and cytokines in mood disorders.
Nishida A; Hisaoka K; Zensho H; Uchitomi Y; Morinobu S; Yamawaki S
Int Immunopharmacol; 2002 Nov; 2(12):1619-26. PubMed ID: 12469936
[TBL] [Abstract][Full Text] [Related]
33. In vivo evidence for reduced cortical glutamate-glutamine cycling in rats treated with the antidepressant/antipanic drug phenelzine.
Yang J; Shen J
Neuroscience; 2005; 135(3):927-37. PubMed ID: 16154287
[TBL] [Abstract][Full Text] [Related]
34. [Glutamatergic conception of mood disorders].
Permoda-Osip A; Rybakowski J
Psychiatr Pol; 2011; 45(6):875-88. PubMed ID: 22335130
[TBL] [Abstract][Full Text] [Related]
35. Glia mechanisms in mood regulation: a novel model of mood disorders.
Lee Y; Gaskins D; Anand A; Shekhar A
Psychopharmacology (Berl); 2007 Mar; 191(1):55-65. PubMed ID: 17225169
[TBL] [Abstract][Full Text] [Related]
36. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond.
Krystal JH; Sanacora G; Duman RS
Biol Psychiatry; 2013 Jun; 73(12):1133-41. PubMed ID: 23726151
[TBL] [Abstract][Full Text] [Related]
37. Novel drugs and therapeutic targets for severe mood disorders.
Mathew SJ; Manji HK; Charney DS
Neuropsychopharmacology; 2008 Aug; 33(9):2080-92. PubMed ID: 18172433
[TBL] [Abstract][Full Text] [Related]
38. Clinical studies implementing glutamate neurotransmission in mood disorders.
Sanacora G; Rothman DL; Mason G; Krystal JH
Ann N Y Acad Sci; 2003 Nov; 1003():292-308. PubMed ID: 14684453
[TBL] [Abstract][Full Text] [Related]
39. Glutamatergic modulators: the future of treating mood disorders?
Zarate C; Machado-Vieira R; Henter I; Ibrahim L; Diazgranados N; Salvadore G
Harv Rev Psychiatry; 2010; 18(5):293-303. PubMed ID: 20825266
[TBL] [Abstract][Full Text] [Related]
40. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.
Sanacora G; Zarate CA; Krystal JH; Manji HK
Nat Rev Drug Discov; 2008 May; 7(5):426-37. PubMed ID: 18425072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
